课题基金 / 基金详情

PHASE I CH14.18 AND R24 MOAB AND IL-2 FOR PATIENTS WITH GD2+/GD3+

PHASE I CH14.18 AND R24 MOAB AND IL-2 FOR PATIENTS WITH GD2+/GD3+
用于 GD2 /GD3 患者的 I 期 CH14.18 和 R24 MOAB 和 IL-2
批准号：
6252778
负责人：
MARK R ALBERTINI
金额：
$1.75万
依托单位：
UNIVERSITY OF WISCONSIN-MADISON
依托单位国家：
美国
项目类别：
财政年份：
1997
资助国家：
美国
项目状态：
已结题
起止时间：
1997-01-28 至 1997-11-30
来源：
https://reporter.nih.gov/project-details/6252778
关键词：
blood /lymphatic neoplasm cell mediated cytotoxicity clinical research clinical trial phase I dosage drug screening /evaluation gangliosides human subject human therapy evaluation interleukin 2 monoclonal antibody neoplasm /cancer immunotherapy pharmacokinetics

项目成果

MARK R ALBERTINI的其他基金

相似基金

相关文献

期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Administration of intratumoral immunocytokine to activate immune rejection of spontaneous canine melanoma
Administration of intratumoral immunocytokine to activate immune rejection of spontaneous canine melanoma
Administration of intratumoral immunocytokine to activate immune rejection of spontaneous canine melanoma
Administration of intratumoral immunocytokine to activate immune rejection of spontaneous canine melanoma
海外基金